| 10.12 -0.13 (-1.27%) | 09-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 14.06 | 1-year : | 16.42 |
| Resists | First : | 12.03 | Second : | 14.06 |
| Pivot price | 10.46  |
|||
| Supports | First : | 8.62 | Second : | 6.51 |
| MAs | MA(5) : | 10.68 |
MA(20) : | 9.79 |
| MA(100) : | 9.83 |
MA(250) : | 13.81 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 62.2 |
D(3) : | 71.8 |
| RSI | RSI(14): 51 |
|||
| 52-week | High : | 49.59 | Low : | 3.01 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AKTX ] has closed above bottom band by 31.5%. Bollinger Bands are 62.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 11.02 - 11.09 | 11.09 - 11.14 |
| Low: | 9.61 - 9.69 | 9.69 - 9.75 |
| Close: | 9.85 - 9.97 | 9.97 - 10.06 |
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Tue, 08 Sep 2026
A biotech CEO will present a new cancer-drug approach at five U.S. and China conferences - Stock Titan
Thu, 27 Aug 2026
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference - GlobeNewswire
Tue, 18 Aug 2026
Akari’s cancer treatment candidate slowed tumors after they resisted Trodelvy in lab tests - Stock Titan
Tue, 26 May 2026
Why Akari Therapeutics Stock Is Falling On Tuesday? - benzinga.com
Fri, 22 May 2026
Akari Therapeutics gains on positive preclinical data for cancer therapy (AKTX:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 15.5 (%) |
| Held by Institutions | 12.2 (%) |
| Shares Short | 38 (K) |
| Shares Short P.Month | 16 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.61 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.2 % |
| Return on Equity (ttm) | -140.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0.93 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.81 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|